Clinical Trials
The study will be available in electronic form, after an order is received, within 6 days.
This study was compiled by STOCHASIS Management Consultancy S.A. and aims to reflect the current state of the Clinical Trials in Greece and to examine its prospects, while presenting information on the international market.
More specifically, the first five chapters of the study feature information on the Clinical Trials, which refer to general characteristics, the institutional framework, the demand, the offer and the size of the industry. In the sixth chapter of the study we will present information on the relevant market internationally. Finally, we will present the conclusions and the prospects of the market, as well as an annex with selected financial indicators of major enterprises in 2011-2013.
The basic factors that influence the demand for clinical studies are:
The financial status of the clinical studies companies is defined as satisfactory, since the companies are not significantly influenced by the domestic macroeconomical environment.
This study was compiled by STOCHASIS Management Consultancy S.A. and aims to reflect the current state of the Clinical Trials in Greece and to examine its prospects, while presenting information on the international market.
More specifically, the first five chapters of the study feature information on the Clinical Trials, which refer to general characteristics, the institutional framework, the demand, the offer and the size of the industry. In the sixth chapter of the study we will present information on the relevant market internationally. Finally, we will present the conclusions and the prospects of the market, as well as an annex with selected financial indicators of major enterprises in 2011-2013.
The basic factors that influence the demand for clinical studies are:
- The research & development expenses by the pharmaceutical companies, 70% of which concerns clinical studies
- The regulatory framework
- The expertise and the human resources cost, in the area of health and research
The financial status of the clinical studies companies is defined as satisfactory, since the companies are not significantly influenced by the domestic macroeconomical environment.
SYNOPSIS
INTRODUCTION
1. GENERAL INFORMATION
1.1 Definition andcategories
1.2 Budgetand procedures
2. INSTITUTIONAL FRAMEWORK
3. DEMAND
3.1 Determinants of demand
3.2 Analysis of selected determinants of demand
4. OFFER
4.1 Financial industry analysis(2011-2013)
5 MARKET
5.1 Number and value of clinical studies
5.2 Structure of clinical studies per phase
5.3 Sponsors of clinical studies
5.4 Clinical studies per illness
5.5 Clinical studies per age group and gender
5.6 Approval time per clinical study
5.7 Countries input in the clinical studies elaboration.
5.8 Research& medicine development
5.9 Turnover development of the major enterprises
5.10 Porter's five forces
6. EUROPEAN MARKET
6.1 Clinical studies internationally
6.2 Clinical studies in Europe
6.3 Clinical studies per European Country
6.4 Research and development expenses internationally
7. CONCLUSIONS AND PROSPECTS -SUGGESTIONS
7.1 SWOT Analysis
7.2 Main findings-Prospects
ANNEX
Financial ratios of major enterprises of the industry
A. Capital structure indicators and financial leverage
B. Liquidity indicators
C. Activity indicators
D. Performance indicators
Types of financial indicators
SOURCES & BIBLIOGRAPHY
INTRODUCTION
1. GENERAL INFORMATION
1.1 Definition andcategories
1.2 Budgetand procedures
2. INSTITUTIONAL FRAMEWORK
3. DEMAND
3.1 Determinants of demand
3.2 Analysis of selected determinants of demand
4. OFFER
4.1 Financial industry analysis(2011-2013)
5 MARKET
5.1 Number and value of clinical studies
5.2 Structure of clinical studies per phase
5.3 Sponsors of clinical studies
5.4 Clinical studies per illness
5.5 Clinical studies per age group and gender
5.6 Approval time per clinical study
5.7 Countries input in the clinical studies elaboration.
5.8 Research& medicine development
5.9 Turnover development of the major enterprises
5.10 Porter's five forces
6. EUROPEAN MARKET
6.1 Clinical studies internationally
6.2 Clinical studies in Europe
6.3 Clinical studies per European Country
6.4 Research and development expenses internationally
7. CONCLUSIONS AND PROSPECTS -SUGGESTIONS
7.1 SWOT Analysis
7.2 Main findings-Prospects
ANNEX
Financial ratios of major enterprises of the industry
A. Capital structure indicators and financial leverage
B. Liquidity indicators
C. Activity indicators
D. Performance indicators
Types of financial indicators
SOURCES & BIBLIOGRAPHY
